After percutaneous coronary intervention, ticagrelor alone or with aspirin are equally effective in preventing repeat revascularization at one year in a post-hoc TWILIGHT analysis.
Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported. The TWILIGHT trial, for which the main results were presented at TCT 2019, evaluated the efficacy and safety of ticagrelor plus aspirin compared with ticagrelor alone for bleeding and ischemic
LAS VEGAS — In a comparison of two vascular closure devices used in transfemoral transcatheter aortic valve replacement procedures, the Perclose ProGlide device was associated with lower rates of vascular complications and acute kidney injury compared with the Prostar XL device, according to new data from the BRAVO 3 trial.
In a post hoc analysis of BRAVO 3 presented at the Society for
CAD does not increase short-term risk, major bleeding after TAVR healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
1. In this secondary analysis of the HOST-EXAM randomized clinical trial, clopidogrel monotherapy was associated with lower rates of the composite end point of all-cause death, myocardial infarction, stroke, readmission due to acute coronary syndrome, and major bleeding in patients with and without diabetes. 2. The presence of diabetes was not associated with a difference